Avanos Medical is deeply undervalued, with strong international expansion, aggressive M&A strategy, and a new CFO poised to drive inorganic growth. AVNS operates in high-growth markets, maintains a solid balance sheet with low debt, and trades at a significant discount to sector peers on earnings and book value. Ongoing transformation, divestitures, and stock repurchases are expected to enhance...
ALPHARETTA, Ga. , Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas.
Avanos Medical, Inc. appears deeply undervalued after years of restructuring, with a potential stabilization in sales and earnings projected for 2025. Recent tariff impacts and lowered guidance seem fully priced in, setting the stage for upside surprises and a share price rally into 2026. Insider buying and improving technical indicators suggest a sea change for investor confidence could be next.
Avanos Medical, Inc. (NYSE:AVNS ) Q2 2025 Earnings Conference Call August 5, 2025 9:00 AM ET Company Participants David C. Pacitti - Chief Executive Officer Jason M.
ALPHARETTA, Ga. , Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025.
ALPHARETTA, Ga. , July 31, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), announced today the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC (CMM), a privately held company based in Raleigh, NC.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.